PURPOSE OF REVIEW: Ischemic preconditioning (IPC) is gaining attention as a novel neuroprotective therapy and could provide an improved mechanistic understanding of tolerance to cerebral ischemia. The purpose of this article is to review the recent work in the field of IPC and its applications to clinical scenarios. RECENT FINDINGS: The cellular signaling pathways that are activated following IPC are now better understood and have enabled investigators to identify several IPC mimetics. Most of these studies were performed in rodents, and efficacy of these mimetics remains to be evaluated in human patients. Additionally, remote ischemic preconditioning (RIPC) may have higher translational value than IPC. Repeated cycles of temporary ischemia in a remote organ can activate protective pathways in the target organ, including the heart and brain. Clinical trials are underway to test the efficacy of RIPC in protecting brain against subarachnoid hemorrhage. SUMMARY: IPC, RIPC, and IPC mimetics have the potential to be therapeutic in various clinical scenarios. Further understanding of IPC-induced neuroprotection pathways and utilization of clinically relevant animal models are necessary to increase the translational potential of IPC in the near future.
PURPOSE OF REVIEW: Ischemic preconditioning (IPC) is gaining attention as a novel neuroprotective therapy and could provide an improved mechanistic understanding of tolerance to cerebral ischemia. The purpose of this article is to review the recent work in the field of IPC and its applications to clinical scenarios. RECENT FINDINGS: The cellular signaling pathways that are activated following IPC are now better understood and have enabled investigators to identify several IPC mimetics. Most of these studies were performed in rodents, and efficacy of these mimetics remains to be evaluated in humanpatients. Additionally, remote ischemic preconditioning (RIPC) may have higher translational value than IPC. Repeated cycles of temporary ischemia in a remote organ can activate protective pathways in the target organ, including the heart and brain. Clinical trials are underway to test the efficacy of RIPC in protecting brain against subarachnoid hemorrhage. SUMMARY: IPC, RIPC, and IPC mimetics have the potential to be therapeutic in various clinical scenarios. Further understanding of IPC-induced neuroprotection pathways and utilization of clinically relevant animal models are necessary to increase the translational potential of IPC in the near future.
Authors: Kunjan R Dave; Christian Lange-Asschenfeldt; Ami P Raval; Ricardo Prado; Raul Busto; Isabel Saul; Miguel A Pérez-Pinzón Journal: J Neurosci Res Date: 2005-12-01 Impact factor: 4.164
Authors: Theresa A Lusardi; Carol D Farr; Craig L Faulkner; Giuseppe Pignataro; Tao Yang; Jingquan Lan; Roger P Simon; Julie A Saugstad Journal: J Cereb Blood Flow Metab Date: 2009-12-16 Impact factor: 6.200
Authors: Katsuya Tanaka; Dorothee Weihrauch; Lynda M Ludwig; Judy R Kersten; Paul S Pagel; David C Warltier Journal: Anesthesiology Date: 2003-04 Impact factor: 7.892
Authors: Steven R Zeiler; Robert Hubbard; Ellen M Gibson; Tony Zheng; Kwan Ng; Richard O'Brien; John W Krakauer Journal: Neurorehabil Neural Repair Date: 2015-12-31 Impact factor: 3.919
Authors: Yuechun Wang; Cesar Reis; Richard Applegate; Gary Stier; Robert Martin; John H Zhang Journal: Exp Neurol Date: 2015-04-18 Impact factor: 5.330
Authors: Tanupriya Agrawal; Gaurav K Gupta; Vikrant Rai; James D Carroll; Michael R Hamblin Journal: Dose Response Date: 2014-09-22 Impact factor: 2.658
Authors: Oliver Bracko; Valentina Di Pietro; Giacomo Lazzarino; Angela M Amorini; Barbara Tavazzi; Judith Artmann; Eric C Wong; Richard B Buxton; Michael Weller; Andreas R Luft; Susanne Wegener Journal: J Cereb Blood Flow Metab Date: 2014-06-18 Impact factor: 6.200